Reaktionsgleichung
[CH:1]12[CH2:10][CH:5]3[CH2:6][CH:7]([CH2:9][CH:3]([CH2:4]3)[CH:2]1[NH2:11])[CH2:8]2.C1N=CN([C:17](N2C=NC=C2)=[O:18])C=1.CCN(C(C)C)C(C)C.[N:33]1([C:42]([O:44][C:45]([CH3:48])([CH3:47])[CH3:46])=[O:43])[C:37]2([CH2:41][CH2:40][NH:39][CH2:38]2)[CH2:36][CH2:35][CH2:34]1>C(Cl)Cl>[CH:1]12[CH2:10][CH:5]3[CH2:6][CH:7]([CH2:9][CH:3]([CH2:4]3)[CH:2]1[NH:11][C:17]([N:39]1[CH2:40][CH2:41][C:37]3([N:33]([C:42]([O:44][C:45]([CH3:48])([CH3:47])[CH3:46])=[O:43])[CH2:34][CH2:35][CH2:36]3)[CH2:38]1)=[O:18])[CH2:8]2Komponenten
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
A solution of adamantan-2-ylamine (75 mg, 0.38 mmol), CDI (80 mg, 0.46 mmol), i-Pr2NEt (150 mg, 1.14 mmol) in CH2Cl2 (5 mL) was stirred at 0° C. for 1 h, and tert-butyl 1,7-diazaspiro[4.4]nonane-1-carboxylate (100 mg, 0.38 mmol) was added. The reaction mixture stirred at room temperature overnight. The solvent was removed under reduced pressure to give crude product which was purified by preparative TLC to afford tert-butyl 7-(2-adamantylcarbamoyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate (136 mg, 89%). LC-MS Method 3, tR=4.24 min, m/z=404.1; 1H NMR (CDCl3) 1.39 (s, 9H), 1.48-1.52 (m, 4H), 1.62-1.71 (m, 5H), 1.71-1.81 (m, 10H), 1.81-1.88 (m, 3H), 1.89-2.01 (m, 1H), 2.93-3.12 (m, 1H), 3.21 (m, 1H), 3.28-3.49 (m, 2H), 3.55 (m, 1H), 3.68 (m, 1H), 3.88 (m, 1H), 4.46 (m, 1H).
Aufarbeitung
- customThe solvent was removed under reduced pressure
- customto give crude product which
- customwas purified by preparative TLC
Quellen und Nachweise
- ORD-Eintrag
- ord-80deddb8ded445c392942df9ef9c08ce
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08828985B2
Verknüpfte Notizen
Wird geladen…